AMH and ovarian reserve: what the test measures and what it cannot predict

TL;DR

• AMH (anti-Müllerian hormone) is a quantity signal. It is made by the small growing follicles in the ovaries, so it tracks roughly how many of those follicles there are right now. It says nothing direct about egg quality.
• It does one job very well. AMH is a well-established predictor of how many eggs ovarian stimulation is likely to yield in IVF or egg freezing, and of the risk of a poor or excessive response.
• It is not a natural-fertility forecast. In a JAMA study of women aged 30 to 44 without known infertility, low AMH was not associated with lower chances of conceiving over six or twelve months. Outside that population the question is unestablished rather than settled, because the studies that would validate AMH as a personal fertility forecast have not been done.
• It cannot give a menopause date. AMH falls with age, but individual predictions of menopause timing are too imprecise to be useful except at the extremes.
• The number moves for reasons unrelated to reserve. Different laboratory assays give systematically different values, hormonal contraception lowers AMH while it is being used, and AMH typically runs high in polycystic ovary syndrome.
• The value is in the interpretation. Read alongside age, cycle history, FSH and an ultrasound follicle count, by a clinician who knows what decision it is meant to inform, AMH is a genuinely useful test.

Educational content, not medical advice. No doses or protocols appear. No numeric AMH cut-offs or reference ranges are printed on this page, deliberately, because they are assay-specific and age-specific and cannot be applied to an individual result without clinical context.

---

AMH has moved from fertility clinics into direct-to-consumer testing, and with that move it has picked up a reputation it was never designed to carry. A low result is often read as a countdown: fewer years of fertility, an early menopause, a deadline. A normal or high result is often read as reassurance.

Neither reading is reliable. AMH measures something real, and in the right setting it is one of the most useful tests in reproductive medicine. But it measures one thing, and most of the worry it causes comes from asking it to predict others. This page sets out what the evidence supports, where the test is strong, and where it is not.

For the wider hormonal picture of the late reproductive years, see the menopause and perimenopause guide.

What AMH is and which cells make it

Anti-Müllerian hormone is a protein hormone. In women, it is produced by the granulosa cells that line small, early-stage growing follicles in the ovary: the preantral and small antral follicles. Larger follicles that have been selected to ovulate largely stop making it.

Because each of those small follicles contributes, the amount of AMH in the blood broadly reflects how many of them are present. That is why AMH correlates reasonably well with the antral follicle count, the number of small follicles visible on a transvaginal ultrasound, and why both are described as markers of "ovarian reserve".

"Reserve" in this context means quantity. The pool of follicles is set before birth and declines throughout life, and AMH declines with it, becoming very low as menopause approaches. What AMH does not measure is the quality of the eggs inside those follicles. Egg quality, and in particular the chance that an egg is chromosomally normal, is driven mainly by age. Two women with the same AMH but ten years apart in age are in different fertility situations.

AMH is also relatively stable across the menstrual cycle compared with hormones such as FSH and oestradiol, which is part of its practical appeal: it can usually be measured on any day.

What a number does establish

A proxy for follicle quantity

At a population level, AMH reliably tracks the size of the remaining follicle pool. Within a given age group, a woman with a markedly lower AMH generally has fewer small follicles than one with a higher value. That is a genuine piece of biological information.

Prediction of response to ovarian stimulation

This is the test's strongest and best-validated use. In IVF and egg freezing, medicines are used to stimulate several follicles to grow at once. AMH, together with the antral follicle count, is a well-established predictor of how many eggs are likely to be retrieved, and of the risk of a poor response or an excessive response, which matters for the risk of ovarian hyperstimulation. Clinics use it to plan treatment and to set realistic expectations about how many eggs a cycle is likely to yield.

Even here there is a ceiling. Predicting the number of eggs is not the same as predicting a pregnancy. Ovarian reserve tests are much weaker at predicting pregnancy or live birth per treatment cycle, and the European Society of Human Reproduction and Embryology's ovarian stimulation guideline does not recommend them for that purpose. Age remains the more powerful predictor of whether a retrieved egg leads to a baby.

What it cannot predict

Natural fertility

The key study here was published in JAMA in 2017 by Steiner and colleagues. It followed women aged 30 to 44 who had no history of infertility and had been trying to conceive for three months or less, with 750 included in the analysis. Women with low AMH did not have a significantly lower probability of conceiving within six cycles or within twelve cycles than women with normal AMH. High FSH and inhibin B also failed to predict conception. The authors concluded that these markers should not be used to assess natural fertility in women like those studied.

The limits run both ways. The study did not include women with known infertility, women who had already been trying for a long time, or women outside its age range, so it does not show that AMH is irrelevant for them. And it does not make age less important. What it does show is that, for the question "how likely am I to conceive naturally in the next year?", AMH is not the right tool in a general population. That use has not been validated.

Egg quality

AMH reflects how many follicles are growing, not whether their eggs are chromosomally normal. Quality is driven predominantly by age. A reassuring AMH in a woman in her early forties does not offset the age-related fall in egg quality, and a low AMH in a woman in her late twenties does not imply poor-quality eggs.

The date of menopause

Because AMH falls toward undetectable levels as menopause approaches, it seems natural to use it as a countdown. The evidence does not support that for individuals. An individual patient data meta-analysis published in the Journal of Clinical Endocrinology and Metabolism in 2018, pooling 2,596 women of whom 1,077 reached menopause during follow-up, found that AMH was associated with time to menopause, and particularly with early menopause, but that individual predictions of age at menopause had limited precision. The imprecision was greatest for early menopause, which is exactly the case people most want to predict.

There is one important exception. A very low AMH in a younger woman, particularly alongside irregular or absent periods, can be a signal of premature ovarian insufficiency and warrants prompt specialist assessment. That is a reason for investigation, not a timetable. Muscle and bone considerations relevant to an earlier menopause are covered in perimenopause, muscle and bone.

Why results move between labs and across assays and contraception

Different assays, different numbers

AMH is measured by immunoassay, and the assays in clinical use are not interchangeable. In a 2017 analysis in Human Reproduction, Iliodromiti and colleagues compared two widely used automated assays on paired samples from 848 women. One assay read systematically higher than the other, by about 10% on average, with wide individual disagreement. When the results were applied to a treatment-planning algorithm, close to three in ten women would have been placed in a different category depending on which assay was used.

The practical point is simple. A result from one laboratory should not be compared with a result from another and read as a change. Reference ranges are specific to the assay and the laboratory. If a clinician wants to follow AMH over time, it should be measured using the same method.

Hormonal contraception

Hormonal contraception lowers AMH while it is being used. In a 2015 study in Human Reproduction of 887 women attending a fertility assessment clinic, AMH was about 19% lower and the antral follicle count about 18% lower in oral contraceptive users than in non-users, after adjusting for age. A 2021 cross-sectional analysis of more than 27,000 women in the American Journal of Obstetrics and Gynecology found lower AMH with several hormonal methods, including the combined pill, the vaginal ring, the implant and the progestin-only pill, with a smaller difference for the hormonal IUD. That study was funded by a test manufacturer, which is worth noting.

The suppression is generally considered temporary, with case reports describing AMH recovering after contraception is stopped, but the timing of recovery varies. A low result taken while using hormonal contraception needs to be read in that light.

PCOS: why AMH runs high

In polycystic ovary syndrome, AMH typically runs high, because the ovaries contain many small follicles. The 2023 International Evidence-based Guideline for PCOS accepted serum AMH as an alternative to ultrasound for identifying polycystic ovarian morphology in adults, with clear limits: it is not used in adolescents, and neither AMH nor ultrasound is diagnostic on its own. A high AMH is therefore not automatically good fertility news; in the right context it can be one part of a PCOS diagnosis. The condition itself is covered in the PCOS guide.

Other influences

Previous ovarian surgery, some cancer treatments, and certain other medical conditions can all lower AMH. AMH is also only one part of the workup for irregular cycles or fertility concerns; thyroid function, for example, is usually checked alongside it, as covered in thyroid and perimenopause.

When the test is useful

What links the useful situations is that each has a specific clinical decision attached. The least useful situation is the one direct-to-consumer marketing often encourages: a stand-alone number, read alone, interpreted as a forecast.

For anyone trying to conceive without success, the standard advice still applies regardless of AMH: seek assessment after twelve months of trying under age 35, after six months at 35 or over, and sooner if there are known concerns such as irregular periods.

Frequently asked questions

What does an AMH test tell you? It gives an estimate of how many small growing follicles the ovaries currently contain, which is a proxy for ovarian reserve in the sense of quantity. Its best-established use is predicting how many eggs ovarian stimulation is likely to produce in IVF or egg freezing. It does not measure egg quality, does not reliably predict natural fertility in women without known infertility, and cannot give a menopause date.

What does a low AMH mean? It means fewer small follicles than average for the reference group, measured with that particular assay. On its own, it does not mean someone cannot conceive naturally; in women aged 30 to 44 without known infertility, low AMH was not linked to lower conception rates over a year. It can matter for IVF planning, and a very low value in a younger woman warrants specialist assessment. Hormonal contraception and the assay used can both lower the number.

Can AMH predict when I will reach menopause? Not precisely. AMH is associated with the timing of menopause at a population level, but individual predictions have wide margins of error, especially for early menopause. A very low AMH in a younger woman is an important exception and a reason for prompt assessment.

Why is my AMH high? A high AMH reflects many small follicles. It is common in polycystic ovary syndrome, where it can contribute to diagnosis in adults alongside other criteria. A high value is not, on its own, a sign of better fertility, and it needs to be read alongside cycle history and other findings.

Where Vivre Labs fits

The most useful thing to do with an AMH result is to read it alongside a fuller picture. Vivre Labs' baseline hormone and biomarker panel is built for that, and is best read with your own doctor. Vivre Labs also offers kisspeptin-10; its page sets out the evidence and regulatory status, and it is not a fertility treatment and does not change AMH or ovarian reserve.

Related reading

• Menopause and perimenopause guide - what changes through the transition, and the treatment options
• PCOS guide - diagnosis, the role of AMH, and what the condition means beyond fertility
• Thyroid and perimenopause - overlapping symptoms and how to tell them apart
• Optimal vs normal lab ranges - why a reference range is not a verdict
• Part of The Complete Guide to Women's Hormonal Health

---

Get the number read by someone who can put it in context. AMH is most useful when it sits alongside your age, cycle history, FSH and ultrasound findings, and when it is attached to a decision you are actually making. Vivre Labs recommends starting with baseline bloodwork so you have a reference point to discuss with your own doctor. See what to test, or join the founding cohort to book a consult.

Educational content, not medical advice. This page explains what an AMH result can and cannot show. It is not a fertility assessment and does not interpret any individual result. No AMH cut-offs or reference ranges appear because they are assay-specific and must be interpreted clinically. No compound, supplement or protocol is suggested to change AMH or ovarian reserve, and no testing service is named or ranked. No doses, schedules or protocols appear on this page. Anyone trying to conceive without success, or with absent or irregular periods, should seek clinical assessment. Claims for the Malaysian market are subject to MAB requirements. Position stated as of 19 October 2026.

References

• AMH and natural fertility - Steiner AZ, Pritchard D, Stanczyk FZ, et al. Association between biomarkers of ovarian reserve and infertility among older women of reproductive age. JAMA. 2017;318(14):1367-1376. (Women aged 30-44 without known infertility, trying for three months or less; 750 analysed; low AMH not associated with lower probability of conception by six or twelve cycles.) (NICHD release)
• AMH and menopause timing - Depmann M, Eijkemans MJC, Broer SL, et al. Does AMH relate to timing of menopause? Results of an individual patient data meta-analysis. Journal of Clinical Endocrinology and Metabolism. 2018;103(10):3593-3600. (2,596 women, 1,077 reached menopause; individual predictions of limited precision, especially for early menopause.)
• Assay non-equivalence - Iliodromiti S, Salje B, Dewailly D, et al. Non-equivalence of anti-Müllerian hormone automated assays and their implications for use as a companion diagnostic. Human Reproduction. 2017;32(8):1710-1715. (848 women; systematic difference of about 10% between two automated assays; 29.3% would have been assigned a different treatment category.)
• Oral contraception and ovarian reserve markers - Birch Petersen K, Hvidman HW, Forman JL, et al. Ovarian reserve assessment in users of oral contraception seeking fertility advice on their reproductive lifespan. Human Reproduction. 2015;30(10):2364-2375. (887 women; AMH about 19% and antral follicle count about 18% lower in users.)
• Hormonal contraception and AMH - Hariton E, et al. Anti-Müllerian hormone levels among contraceptive users: evidence from a cross-sectional cohort of 27,125 individuals. American Journal of Obstetrics and Gynecology. 2021. (Cross-sectional; authors had financial ties to a test manufacturer.)
• Recovery after stopping - Fox CW, Stanhiser J, Quaas AM. Evidence of profound ovarian suppression on combined hormonal contraception resulting in dramatically different ovarian reserve testing and oocyte retrieval outcomes: case report and review of the literature. F&S Reports. 2020;1(2):94-98.
• PCOS - Teede HJ, Tay CT, Laven JSE, et al. Recommendations from the 2023 International Evidence-based Guideline for the Assessment and Management of Polycystic Ovary Syndrome. 2023. (Serum AMH as an alternative to ultrasound for polycystic ovarian morphology in adults only; not a single diagnostic test.)
• Ovarian stimulation - ESHRE Reproductive Endocrinology Guideline Group. Ovarian stimulation for IVF/ICSI. European Society of Human Reproduction and Embryology guideline, 2019, with 2025 update. (AMH and antral follicle count for predicting ovarian response; ovarian reserve tests not recommended for predicting pregnancy or live birth.)